TransMedics Group, Inc. (TMDX)
$79.14+1.24%Close
SELLRECOVERY · day 7
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.7B
- Beta
- 1.93
- P/E (TTM)
- 17.90
- IV ATM
- 69.4%
- Short % float
- 25.50%
- Days to cover
- 13.1
- SI change
- +7.2%
- 1W
- -1.42%
- 1M
- -7.83%
- vs SPY 1W
- -1.28%
- vs SPY 1M
- -10.33%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 56
- VALUE
- 27
- GROWTH
- 53
- GARP
- 65
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC19.8%
REV YoY-
ROE33.0%
EPS YoY-
ROA10.4%
GROSS59
OP12
NET23
[VALUATION]
P/E TTM17.90
P/E FWD39.62
SECTOR PE20.34
INDUSTRY PE22.66
P/B5.28
P/FCF-
EV/EBITDA24.04
EV/EBIT-
PEG0.73
FCF YIELD-
RISK
INT COV-
D/E167.50
ALTMAN Z-
CURR RATIO6.62
ND/EBITDA-
BETA1.93
Company news
FAQ
- What is LOPJLB’s current signal on TMDX?
- LOPJLB’s latest quantitative signal on TransMedics Group, Inc. (TMDX) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is TMDX in?
- TransMedics Group, Inc. (TMDX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does TransMedics Group, Inc. (TMDX) do?
- TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system …